Spinraza access in India

Quick orientation

Spinraza is an antisense oligonucleotide indicated for spinal muscular atrophy (SMA) across all types and all ages, the first approved disease-modifying therapy for SMA anywhere in the world. India's SMA community is large in absolute numbers but the public payer landscape for SMA-modifying therapy is uneven. Spinraza has not been granted full CDSCO registration as of this page's last review, and named-patient import under Rule 36 of the Drugs and Cosmetics Rules 1945 is the established pathway for Indian families who can fund treatment privately. The intrathecal administration requirement gates dispensing to neurology and pediatric neurology programmes with the procedural capability. Reserve Meds coordinates US-side sourcing, cold-chain logistics, and the documentation kit. Reserved for you.

Why patients in India need Spinraza via NPP

Spinal muscular atrophy is a rare inherited neuromuscular disease caused by loss-of-function mutations in the SMN1 gene. In its most severe form (Type 1), SMA is fatal in early childhood without disease-modifying treatment. Less severe forms (Type 2, 3, 4) carry a heavy lifetime burden of progressive motor neuron loss, respiratory compromise, and loss of independent function. India's absolute SMA-affected population is substantial, and the National Policy for Rare Diseases 2021 designates SMA among rare diseases for which one-time financial assistance under the Rashtriya Arogya Nidhi umbrella is contemplated, with a ceiling currently set at INR 50 lakh per patient.

The access gap shows up in three patterns. First, Spinraza is not fully registered with CDSCO, so even for families with means there is no commercial pharmacy stocking the drug in India; named-patient import is the route. Second, the intrathecal administration requirement (lumbar puncture by a trained physician, sometimes with interventional radiology guidance in older patients with scoliosis or prior spinal fusion) concentrates dispensing capability at a small set of centers. Third, even where Biogen has commercial presence in India, the every-four-months maintenance schedule and the per-dose price point mean that families who fall outside any reimbursement framework default to cash-pay.

For families with a child or adult relative diagnosed with SMA, the option set in India is Spinraza, risdiplam (Evrysdi, oral daily small molecule), or onasemnogene abeparvovec (Zolgensma, one-time gene therapy for children under two). The clinical decision rests with the treating neurologist. Spinraza has the longest real-world evidence base and works across all SMA types and ages including adults; it is often the choice where intrathecal access is feasible and the family prefers an established mechanism with long-term safety data.

The CDSCO named-patient pathway for Spinraza

The legal foundation for personal import of unregistered medicines into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits import of small quantities of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application; Form 12B is the permit issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan in New Delhi, or by designated CDSCO Port Offices. The quantity of any single drug imported shall not exceed one hundred average doses per application.

For Spinraza, the application packages: the treating neurologist's prescription with the National Medical Commission (NMC) registration number; the SMA diagnosis confirmation (genetic testing demonstrating homozygous SMN1 deletion or compound heterozygous SMN1 mutation, SMN2 copy number, and SMA type classification); the dosing plan referencing the FDA label (four loading doses at days 0, 14, 28, and 63, then maintenance every four months); a chain-of-custody plan from the US wholesaler or Biogen channel to the dispensing facility in India; and the dispensing facility's drug licence (hospital pharmacy or licensed importer's wholesale licence).

The clinical justification angle for Spinraza centers on the genetic confirmation, the SMA type and current functional status, the prior-therapy history (if any) including whether risdiplam or Zolgensma have been considered or attempted, and the rationale for intrathecal nusinersen specifically. For pediatric Type 1 cases, time-to-first-dose pressure is acute; for older Type 2 and Type 3 cases the cadence is steadier but the every-four-months maintenance schedule requires sustained continuity. CDSCO published guidance indicates that Form 12B permits issue on a priority basis, typically within one to two days for routine applications where the documentation is complete; in practice the two to four week window from physician decision to dispensed medicine covers upstream documentation assembly and downstream international logistics.

Compassionate Use of unapproved drugs sought by hospitals or registered medical practitioners through the DCGI office is a parallel route, used when the drug is approved by a recognised reference authority (FDA, EMA, MHRA, Health Canada, PMDA) for a life-threatening condition, a serious permanent disability, or an unmet medical need. AIIMS and Tata Memorial Centre have established workflow on this pathway.

Where Spinraza gets dispensed in India

The intrathecal administration requirement subsets the dispensing map to neurology and pediatric neurology programmes with the procedural capability. The institutions that handle named-patient and compassionate imports as established workflow, and that maintain the neurology and pediatric neurology infrastructure for intrathecal Spinraza, include All India Institute of Medical Sciences (AIIMS), New Delhi (designated Centre of Excellence under the National Policy for Rare Diseases); Tata Memorial Centre, Mumbai; Christian Medical College (CMC), Vellore (long-standing neurology programme); Apollo Hospitals (Chennai, Delhi, Bangalore, Hyderabad); Fortis Healthcare (Fortis Memorial Research Institute Gurgaon, Mulund Mumbai, Bangalore); Medanta in Gurgaon; Kokilaben Dhirubhai Ambani Hospital in Mumbai; MGM Healthcare in Chennai; and Manipal Hospitals in Bangalore.

For older SMA Type 2 and Type 3 patients with scoliosis, prior spinal fusion, or other anatomic challenges, the intrathecal procedure sometimes requires interventional radiology guidance, which further concentrates capability at tertiary centers with neuro-interventional capacity. Pediatric Type 1 cases route through pediatric neurology programmes at AIIMS, Tata Memorial, CMC Vellore, Apollo, Kokilaben, and other pediatric tertiary institutions.

For families resident outside major metropolitan areas, the practical model is travel to the dispensing center for each scheduled dose. The every-four-months maintenance cadence is feasible from anywhere in the country if the loading-phase center is chosen with that constraint in mind. Reserve Meds' single named coordinator model carries this travel coordination as part of the case file.

Real cost picture for Spinraza in India

The US wholesale acquisition cost for Spinraza is approximately USD 125,000 per 12 mg vial (Biogen-stated WAC at launch in late 2016, maintained as the reference WAC since). First-year cost (six doses: four loading plus two maintenance) is approximately USD 750,000. Subsequent years (three maintenance doses per year) run approximately USD 375,000 per year. At the USD/INR rate in the 94 to 95 range in May 2026, the per-dose drug cost converts to approximately INR 1.17 to 1.19 crore.

International list prices vary by country and are typically negotiated downward from US WAC by national payers; cash-pay private-import pricing in India typically reflects ex-US wholesaler pricing plus Reserve Meds coordination fee, customs duty and GST where applicable, refrigerated air freight, and treatment-center procedural costs. The Reserve Meds quote is a transparent line-item structure: drug, international logistics (USD 400 to 1,500 per shipment depending on cold-chain configuration and routing), regulatory documentation handling, customs handling, and concierge coordination fee.

Indian private insurer behavior is variable. Star Health, HDFC ERGO, ICICI Lombard, and Niva Bupa each handle SMA therapy on a case-by-case basis; none reimburse Spinraza as a standard line item. Some have reimbursed full or partial drug cost where the underlying medicine fits the plan's rare-disease provisions. CGHS provides for life-saving medicines not in the standard formulary to be considered case-by-case by an Expert Committee under Special DG (DGHS) for central government employees and pensioners. The National Policy for Rare Diseases 2021 ceiling under Rashtriya Arogya Nidhi (INR 50 lakh per patient) is relevant for some cohorts. Cash-pay remains the default operating posture. Union Budget 2026-27 expanded the customs duty exemption list for life-saving and rare-disease drugs; HSN applicability for any specific Spinraza shipment is confirmed at the documentation stage.

Typical timeline for Spinraza

Rule 36 documentation runs the standard one to two days at CDSCO for routine applications with complete paperwork, with the practical two to four week window covering upstream documentation assembly (genetic confirmation, NMC-signed prescription, dispensing facility licence, chain-of-custody plan) and downstream international logistics (refrigerated air freight in validated 2 to 8 C shippers, customs clearance at Delhi, Mumbai, Bangalore, Chennai, or Hyderabad). The 14-day room-temperature stability window per the FDA label provides operational tolerance for customs delays. After arrival, the dispensing facility schedules the lumbar puncture; the dosing schedule then follows the FDA label (days 0, 14, 28, 63 for loading, then every four months indefinitely). For pediatric Type 1 cases, time-to-first-dose pressure is acute, and Reserve Meds pre-stages cold-chain logistics at intake. For Type 2, 3, and 4 cases the cadence is steadier but continuous over years.

What your physician needs to provide

The clinical justification letter for a Spinraza case is signed by a treating neurologist or pediatric neurologist holding an active NMC registration number with state council registration where required. The letter addresses the SMA diagnosis with ICD-10 coding (G12.x), the genetic confirmation (homozygous SMN1 deletion or compound heterozygous SMN1 mutation by validated genetic testing, with SMN2 copy number documented), the SMA type classification, the current functional status (CHOP-INTEND for infants, HFMSE or RULM for older patients, ambulation status), any prior therapy attempted (risdiplam, Zolgensma) with outcomes, and the clinical case for intrathecal nusinersen specifically.

The dosing reference is the FDA label: 12 mg (one full 5 mL vial) per intrathecal administration, no weight adjustment; four loading doses at days 0, 14, 28, and 63; maintenance every four months indefinitely. The monitoring plan covers the per-label safety labs (platelet count, coagulation testing, quantitative spot urine protein at baseline and prior to each dose; renal function with serum creatinine and cystatin C periodically). The treating center performs these labs on the day of or in the days before each scheduled dose.

Two safety warnings carry operational weight: thrombocytopenia and coagulation abnormalities including acute severe thrombocytopenia, and renal toxicity including potentially fatal glomerulonephritis. The intrathecal procedure itself carries the usual lumbar puncture risks. The documentation kit references the FDA prescribing information so the treating physician's monitoring plan aligns. Adverse event reporting through the Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission, applies for every imported dose and is referenced in the documentation kit; the reporting obligation itself stays with the prescribing physician.

Common questions about Spinraza in India

Will Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa cover Spinraza? Each plan handles SMA therapy on a case-by-case basis. None of the major Indian private insurers reimburse Spinraza as a standard line item. Some have reimbursed full or partial drug cost where the underlying medicine fits the plan's rare-disease provisions. Reserve Meds provides documentation that lets a payer evaluate; the claim itself is filed by the patient or family. Cash-pay is the default operating posture.

Will CGHS or the Rashtriya Arogya Nidhi NPRD ceiling cover this? CGHS provides for life-saving medicines not in the standard formulary to be considered case-by-case by an Expert Committee under Special DG (DGHS), with stricter Expert Committee review for drugs not approved by CDSCO. The Rashtriya Arogya Nidhi ceiling under NPRD 2021 is currently INR 50 lakh per patient; for SMA this is meaningful but does not cover lifetime therapy. Check eligibility with your CGHS Wellness Centre or designated Centre of Excellence under NPRD.

Can my child receive the lumbar puncture in our home city? The dispensing facility must hold a valid drug licence and the procedural capability for intrathecal administration. AIIMS, Tata Memorial, CMC Vellore, Apollo, Fortis, Medanta, Kokilaben, MGM, and Manipal handle pediatric SMA cases routinely. For older patients with scoliosis or prior spinal fusion, interventional radiology guidance may be required, which concentrates capability further. Reserve Meds matches the dispensing facility to the patient's anatomic and geographic context.

Why Spinraza versus Evrysdi or Zolgensma? Spinraza has the longest real-world evidence base in SMA and works across all SMA types and all ages, including adult patients. Evrysdi (risdiplam) is oral daily, preferred where oral administration is critical or intrathecal access is difficult. Zolgensma is a one-time gene therapy restricted by FDA label to children under two years, with a different safety profile and a single administration. The clinical decision rests with the treating neurologist. Reserve Meds does not advise on therapeutic selection.

What about adults with SMA Type 3? The FDA label for Spinraza is age-agnostic. Real-world evidence in adults with SMA Type 3 has shown functional stabilization in many patients, though the magnitude of benefit varies. The CHERISH trial demonstrated motor function benefit in later-onset SMA. Adult cases follow the same Rule 36 pathway as pediatric cases.

Is there a high-dose regimen now? In 2026 the FDA approved a higher-dose Spinraza regimen with faster loading and higher maintenance. The classic regimen described above remains the standard reference; the high-dose regimen may apply for specific cases and is documented in the most recent FDA label revision. The treating neurologist confirms the appropriate dosing schedule.

Where Reserve Meds fits in Spinraza cases

Reserve Meds is a US-based concierge coordinator. For a Spinraza inquiry from an Indian family, the working unit is US-side sourcing through Biogen's regional commercial channel or validated specialty wholesaler, refrigerated air freight in validated 2 to 8 C shippers, customs and chain-of-custody documentation, India-side coordination with the treating neurology programme on the every-four-months maintenance schedule, and a single named coordinator who carries the case across years of recurring doses. The clinical decisions remain with the treating neurologist. The regulatory authority remains CDSCO and the DCGI office in New Delhi. The intrathecal administration remains with the dispensing facility's neurology team.

What Reserve Meds carries: identification of a dispensing facility that matches the patient's anatomic and geographic context, preparation of the Rule 36 documentation kit including the genetic confirmation and the FDA-label-aligned monitoring plan, coordination of refrigerated logistics dose-by-dose, single-coordinator continuity across the multi-year maintenance arc, and the PvPI reference for the prescribing physician's reporting obligation. Reserved for you.

Next step

If your family is considering Spinraza for SMA, the first step is a coordinated intake that confirms eligibility, identifies the appropriate dispensing facility for both the loading phase and the multi-year maintenance schedule, and produces a transparent firm quote. The waitlist request prefills the relevant context so the coordinator who reaches out is already oriented to your case.

Join the Spinraza waitlist

Reserved for you.